Ranked #1,054 of 8,699 institutional investors
TCG Crossover Management, LLC
Palo Alto, CA
$3.40B
US stock portfolio at live prices · today +$5.6M (+0.17%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $3.54B
- Change from Q2 2026
- −$620.7M (−14.92%)
- Positions
- 49 · 5 new, 3 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$130M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesCGON 8.84%ABVX 8.69%SYRE 5.46%AMLX 4.81%KRSA 4.74%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | 3,670,206 | $301M | 8.84% | Unchanged |
| ABVX ABIVAX Société Anonyme | 3,663,038 | $295M | 8.69% | Reduced −39% |
| SYRE Spyre Therapeutics, Inc. | 1,900,582 | $186M | 5.46% | Unchanged |
| AMLX Amylyx Pharmaceuticals, Inc. | 6,243,812 | $164M | 4.81% | Unchanged |
| KRSA Korsana Biosciences, Inc. | 4,549,587 | $161M | 4.74% | New |
| TNGX Tango Therapeutics, Inc. | 6,773,043 | $154M | 4.53% | Reduced −25% |
| IMVT Immunovant, Inc. | 4,457,988 | $145M | 4.26% | Unchanged |
| DNTH Dianthus Therapeutics, Inc. | 1,676,624 | $142M | 4.18% | Unchanged |
| KOD Kodiak Sciences Inc. | 1,445,538 | $142M | 4.16% | Unchanged |
| ZLAB Zai Lab Limited | 6,229,081 | $137M | 4.02% | Added +1% |
| TRAX First Tracks Biotherapeutics, Inc. | 2,895,304 | $129M | 3.79% | Unchanged |
| MIRM Mirum Pharmaceuticals, Inc. | 1,118,967 | $107M | 3.14% | Added +5% |
| VOR Vor Biopharma Inc. | 5,673,078 | $105M | 3.09% | Unchanged |
| IRON Disc Medicine, Inc. | 1,341,862 | $102M | 3.00% | Unchanged |
| BCRX BioCryst Pharmaceuticals, Inc. | 11,020,968 | $80.7M | 2.37% | Unchanged |
| DYN Dyne Therapeutics, Inc. | 4,615,144 | $74.0M | 2.18% | Unchanged |
| AURA Aura Biosciences, Inc. | 10,165,357 | $71.0M | 2.09% | Added +7% |
| XNCR Xencor, Inc. | 2,055,938 | $69.9M | 2.06% | Reduced −16% |
| COGT Cogent Biosciences, Inc. | 2,500,003 | $69.4M | 2.04% | Reduced −49% |
| TYRA Tyra Biosciences, Inc. | 3,475,980 | $68.6M | 2.02% | Added +7% |
| SVRA Savara Inc. | 12,362,205 | $64.4M | 1.89% | Unchanged |
| RLAY Relay Therapeutics, Inc. | 3,783,529 | $60.2M | 1.77% | Reduced −11% |
| ADRX ADARx Pharmaceuticals, Inc. | 4,116,452 | $58.3M | 1.71% | New |
| SLN Silence Therapeutics plc | 1,819,035 | $36.0M | 1.06% | Reduced −40% |
| MBX MBX Biosciences, Inc. | 650,000 | $34.7M | 1.02% | Unchanged |
| GLUE Monte Rosa Therapeutics, Inc. | 3,781,532 | $33.7M | 0.99% | Reduced −18% |
| LBRX LB Pharmaceuticals Inc | 765,050 | $30.6M | 0.90% | Reduced −47% |
| TARS Tarsus Pharmaceuticals, Inc. | 388,164 | $30.1M | 0.89% | New |
| OBX Obsidian Therapeutics, Inc. | 2,196,138 | $26.7M | 0.78% | New |
| TECX Tectonic Therapeutic, Inc. | 1,204,891 | $25.4M | 0.75% | Unchanged |
| IPSC Century Therapeutics, Inc. | 17,754,430 | $23.4M | 0.69% | Unchanged |
| ALEC Alector, Inc. | 10,000,000 | $23.0M | 0.68% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 3,017,120 | $20.4M | 0.60% | Unchanged |
| EDIT Editas Medicine, Inc. | 11,111,111 | $19.0M | 0.56% | Unchanged |
| JANX Janux Therapeutics, Inc. | 1,789,617 | $18.4M | 0.54% | Unchanged |
| MNPR Monopar Therapeutics Inc. | 202,242 | $14.2M | 0.42% | Reduced −1% |
| AGMB AgomAb Therapeutics NV | 1,820,831 | $10.2M | 0.30% | Reduced −11% |
| CATX Perspective Therapeutics, Inc. | 7,915,567 | $6.2M | 0.18% | Unchanged |
| KRRO Korro Bio, Inc. | 416,301 | $5.1M | 0.15% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 1,060,230 | $4.9M | 0.14% | Unchanged |
| ARVN Arvinas, Inc. | 707,098 | $4.8M | 0.14% | Unchanged |
| OCUL Ocular Therapeutix, Inc. | 720,323 | $4.2M | 0.12% | Reduced −56% |
| AGEN Agenus Inc. | 603,892 | $3.7M | 0.11% | New |
| CGEM Cullinan Therapeutics, Inc. | 406,786 | $3.7M | 0.11% | Unchanged |
| ALXO ALX Oncology Holdings Inc. | 2,465,436 | $2.5M | <0.1% | Reduced −56% |
| AKTS Aktis Oncology, Inc. | 133,457 | $2.2M | <0.1% | Reduced −81% |
| LONA LeonaBio, Inc. | 464,398 | $1.1M | <0.1% | Unchanged |
| CNTX Context Therapeutics Inc. | 2,682,696 | $452K | <0.1% | Unchanged |
| EIKN Eikon Therapeutics, Inc. | 37,902 | $180K | <0.1% | Unchanged |